PPCB
Propanc Biopharma, Inc.0.7310
-0.0254-3.36%
Dec 16, 4:00:01 PM EST
Earnings Call Transcripts
This Quarter (Q1 '26)
No earnings call transcript available yet
Last Quarter (Q4 '25)
No earnings call transcript available
Key Stats
Market Cap
9.77MP/E (TTM)
0.00Basic EPS (TTM)
272.52Dividend Yield
0%Recent Filings
8-K
Board swap: Kenyon out, Brandt in
Propanc Biopharma's board saw Dr. Julian Kenyon retire effective February 20, 2026, to prioritize family, while appointing oncology veteran Dr. Ralf Brandt in his place. Brandt, with 30+ years advancing 50 compounds to clinic, earns $45,000 annually plus expenses. Smooth transition bolsters expertise.
10-Q
Q2 FY2026 results
Propanc Biopharma posted Q2 FY2026 operating loss of $3.7M, up sharply y/y from $0.2M (derived), driven by $3.6M administration expenses—mostly stock-based comp for consulting—while R&D fell to $20K from $54K. Six-month net loss hit $7.9M versus $0.8M prior (derived), with EPS $(0.30) on 13.4M shares aligning to diluted weighted average; anti-dilution caps excluded 2.4M potential shares. Cash climbed to $561K on $3.3M equity raise and $1.0M Series C preferred (November 2025, $10K stated value per share), funding $2.9M ops burn; related-party loans at $472K in default. Prepaids cover services. Litigation brews with Helena Partners over break fees.
8-K
Nasdaq bid price deficiency notice
Propanc Biopharma received a Nasdaq notice on December 31, 2025, for failing the $1.00 minimum bid price rule after 35 consecutive business days below it. The company has 180 days until June 30, 2026, to regain compliance by hitting $1.00 for 10 straight days. No immediate delisting. Delisting risks slashing liquidity and fundraising.
10-Q
Q1 FY2026 results
Propanc Biopharma posted a $4.8M net loss for Q1 FY2026 ended September 30, 2025, up sharply y/y from $0.4M, driven by $4.6M administration expenses (derived) tied to $3.8M stock-based consulting amortization while R&D held steady at $60K. No revenue yet as a clinical-stage biotech; operating cash burn hit $1.9M, offset by $3.3M net from August's 1M-share offering at $4/share and $0.6M cash end-Q. Debt pared to $0.5M related-party loans (12% rate, some in default) plus $0.1M convertibles from $5.7M q/q. Equity swelled to $14.4M on issuances. Prepaid services loom large at $17M. Clinical delays shadow progress.
8-K
Closes Series C preferred placement
Propanc Biopharma closed a private placement on November 4, 2025, selling 100 shares of newly authorized Series C Preferred Stock to Hexstone Capital for $1,000,099 cash, plus a warrant for 9,900 more shares at $10,000 each. The preferred converts to common at the lesser of $5.00 fixed or 85% of a volume-weighted low price. Cash bolsters liquidity. Terms favor the investor.
CNBX
CNBX Pharmaceuticals Inc.
0.00+0.00
NBTX
Nanobiotix S.A.
22.32+0.18
NCNA
NuCana plc
3.56-0.06
PMCB
PharmaCyte Biotech, Inc.
0.95+0.01
PMVP
PMV Pharmaceuticals, Inc.
1.18-0.02
PROK
ProKidney Corp.
2.20+0.12
PRPO
Precipio, Inc.
24.02-0.04
PTIX
Protagenic Therapeutics, Inc.
1.52-0.07
PVCT
Provectus Biopharmaceuticals, I
0.06+0.00
TARA
Protara Therapeutics, Inc.
5.42-0.08